Skip Nav Destination
Issues
1 February 2019
-
Cover Image
Cover Image
ABOUT THE COVER
In this issue (beginning on page 370), Mooneyham and colleagues demonstrate that UNC-45A is a novel microtubule-associated protein that antagonizes the effect of paclitaxel in ovarian cancer cells, leading to chemoresistance. The immunofluorescent cover image shows strong co-localization between UNC-45A (red) and alpha tubulin (green) in synchronized metaphase HeLa cells. This finding was key in the later identification of UNC-45A as a novel microtubule-associated protein that functions to destabilize microtubules and confer paclitaxel resistance. Together, this study reveals UNC-45A as a promising biomarker and molecular target for paclitaxel-resistant human cancers.
Cover image by Mooneyham not featured in article. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Review
Rapid Impact
Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer
Yuqing Zhang; Amanda Kirane; Huocong Huang; Noah B. Sorrelle; Francis J. Burrows; Michael T. Dellinger; Rolf A. Brekken
Cell Cycle and Senescence
UNC-45A Is a Novel Microtubule-Associated Protein and Regulator of Paclitaxel Sensitivity in Ovarian Cancer Cells
Ashley Mooneyham; Yoshie Iizuka; Qing Yang; Courtney Coombes; Mark McClellan; Vijayalakshmi Shridhar; Edith Emmings; Mihir Shetty; Liqiang Chen; Teng Ai; Joyce Meints; Michael K. Lee; Melissa Gardner; Martina Bazzaro
Cell Death and Survival
Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells
Laure Malric; Sylvie Monferran; Caroline Delmas; Florent Arnauduc; Perrine Dahan; Sabrina Boyrie; Pauline Deshors; Vincent Lubrano; Dina Ferreira Da Mota; Julia Gilhodes; Thomas Filleron; Aurore Siegfried; Solène Evrard; Aline Kowalski-Chauvel; Elizabeth Cohen-Jonathan Moyal; Christine Toulas; Anthony Lemarié
Author Choice
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins; William B. Ainsworth; Paul A. Ellis; Cherrie K. Donawho; Enrico L. DiGiammarino; Sanjay C. Panchal; Vivek C. Abraham; Mikkel A. Algire; Yan Shi; Amanda M. Olson; Eric F. Johnson; Julie L. Wilsbacher; David Maag
DNA Damage and Repair
Genomics
Author Choice
Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate
Habiba Elfandy; Joshua Armenia; Filippo Pederzoli; Eli Pullman; Nelma Pertega-Gomes; Nikolaus Schultz; Kartik Viswanathan; Aram Vosoughi; Mirjam Blattner; Konrad H. Stopsack; Giorgia Zadra; Kathryn L. Penney; Juan Miguel Mosquera; Svitlana Tyekucheva; Lorelei A. Mucci; Christopher Barbieri; Massimo Loda
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Ahmed Basudan; Nolan Priedigkeit; Ryan J. Hartmaier; Ethan S. Sokol; Amir Bahreini; Rebecca J. Watters; Michelle M. Boisen; Rohit Bhargava; Kurt R. Weiss; Maria M. Karsten; Carsten Denkert; Jens-Uwe Blohmer; Jose P. Leone; Ronald L. Hamilton; Adam M. Brufsky; Esther Elishaev; Peter C. Lucas; Adrian V. Lee; Steffi Oesterreich
High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer
Simon Garinet; Géraldine Pignot; Sophie Vacher; Constance Le Goux; Anne Schnitzler; Walid Chemlali; Nanor Sirab; Nicolas Barry Delongchamps; Marc Zerbib; Mathilde Sibony; Yves Allory; Diane Damotte; Ivan Bieche
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells
Kei Namba; Kazuhiko Shien; Yuta Takahashi; Hidejiro Torigoe; Hiroki Sato; Takahiro Yoshioka; Tatsuaki Takeda; Eisuke Kurihara; Yusuke Ogoshi; Hiromasa Yamamoto; Junichi Soh; Shuta Tomida; Shinichi Toyooka
Oncogenes and Tumor Suppressors
Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma
Eric P. Rahrmann; Natalie K. Wolf; George M. Otto; Lynn Heltemes-Harris; Laura B. Ramsey; Jingmin Shu; Rebecca S. LaRue; Michael A. Linden; Susan K. Rathe; Timothy K. Starr; Michael A. Farrar; Branden S. Moriarity; David A. Largaespada
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas
Kristen S. Hill; Evan R. Roberts; Xue Wang; Ellen Marin; Taeeun D. Park; Sorany Son; Yuan Ren; Bin Fang; Sean Yoder; Sungjune Kim; Lixin Wan; Amod A. Sarnaik; John M. Koomen; Jane L. Messina; Jamie K. Teer; Youngchul Kim; Jie Wu; Charles E. Chalfant; Minjung Kim
Signal Transduction
Author Choice
Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1–EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells
Micaela Montanari; Maria Rita Carbone; Luigi Coppola; Mario Giuliano; Grazia Arpino; Rossella Lauria; Agostina Nardone; Felicia Leccia; Meghana V. Trivedi; Corrado Garbi; Roberto Bianco; Enrico V. Avvedimento; Sabino De Placido; Bianca Maria Veneziani
Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
Ida Aronchik; Yumin Dai; Matt Labenski; Carmen Barnes; Terri Jones; Lixin Qiao; Lisa Beebe; Mehnaz Malek; Winfried Elis; Tao Shi; Konstantinos Mavrommatis; Gordon L. Bray; Ellen H. Filvaroff
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.